Has the U.K. Healthcare Services Industry valuation changed over the past few years?

Investors are optimistic on the British Healthcare industry, and appear confident in long term growth rates. The industry is trading at a PE ratio of 49.8x which is higher than its 3-year average PE of 35.9x. The industry is trading close to its 3-year average PS ratio of 0.97x.

Which industries have driven the changes within the U.K. Healthcare industry?

Investors are most optimistic about the Healthcare Services industry even though it's trading below its 3-year average PE ratio of 219x. Analysts are expecting annual earnings growth of 32.8%, which is higher than its past year's earnings decline of 4.8% per year. Investors are most pessimistic about the Healthcare Facilities industry, although it looks like investor sentiment has improved given that it's trading above its 3-year average of 34.0x.

U.K. (FTSE) Healthcare Services Industry Analysis

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Tue, 09 Jun 2026	UK£2.4b	UK£2.6b	UK£48.9m	52.4x	49.8x	0.9x
Thu, 07 May 2026	UK£2.0b	UK£2.5b	UK£44.5m	28.6x	43.9x	0.8x
Sat, 04 Apr 2026	UK£1.9b	UK£2.5b	UK£44.9m	24.9x	41.9x	0.8x
Mon, 02 Mar 2026	UK£2.3b	UK£2.5b	UK£50.4m	29.6x	45.8x	0.9x
Wed, 28 Jan 2026	UK£2.3b	UK£2.4b	UK£57.3m	30.2x	40.4x	0.9x
Fri, 26 Dec 2025	UK£2.1b	UK£2.4b	UK£52.2m	26.9x	41.1x	0.9x
Sun, 23 Nov 2025	UK£2.3b	UK£2.4b	UK£52.1m	30.4x	44.1x	0.9x
Tue, 21 Oct 2025	UK£2.5b	UK£2.4b	UK£52.3m	34.1x	47x	1x
Thu, 18 Sep 2025	UK£5.1b	UK£5.0b	UK£142.0m	31.5x	36x	1x
Sat, 16 Aug 2025	UK£5.0b	UK£5.0b	UK£141.0m	31.5x	35.5x	1x
Mon, 14 Jul 2025	UK£2.1b	UK£2.4b	UK£58.2m	12.5x	36.5x	0.9x
Wed, 11 Jun 2025	UK£2.1b	UK£2.5b	UK£57.0m	14.8x	37.5x	0.9x
Fri, 09 May 2025	UK£2.1b	UK£2.5b	UK£55.5m	14.8x	37.3x	0.8x
Sun, 06 Apr 2025	UK£1.8b	UK£2.4b	UK£46.3m	14.8x	38.6x	0.7x
Tue, 04 Mar 2025	UK£2.0b	UK£2.4b	UK£49.0m	17x	41.5x	0.9x
Thu, 30 Jan 2025	UK£2.1b	UK£2.3b	UK£55.7m	17x	37x	0.9x
Sat, 28 Dec 2024	UK£1.9b	UK£2.3b	UK£55.6m	18.8x	34.6x	0.8x
Mon, 25 Nov 2024	UK£1.9b	UK£2.3b	UK£56.0m	21.1x	33.6x	0.8x
Wed, 23 Oct 2024	UK£2.0b	UK£2.4b	UK£55.0m	19.5x	37x	0.9x
Fri, 20 Sep 2024	UK£2.3b	UK£2.4b	UK£63.7m	24.2x	35.5x	1x
Sun, 18 Aug 2024	UK£2.3b	UK£2.2b	UK£56.5m	20.1x	41.3x	1x
Tue, 16 Jul 2024	UK£2.1b	UK£2.3b	UK£59.0m	16.3x	36x	0.9x
Thu, 13 Jun 2024	UK£2.2b	UK£2.3b	UK£65.1m	17.8x	33.8x	1x
Sat, 11 May 2024	UK£2.1b	UK£2.2b	UK£60.2m	19.1x	35.6x	1x
Mon, 08 Apr 2024	UK£2.1b	UK£2.2b	UK£59.3m	20x	34.7x	0.9x
Wed, 06 Mar 2024	UK£2.4b	UK£2.3b	UK£65.3m	21.8x	37.5x	1.1x
Fri, 02 Feb 2024	UK£7.7b	UK£6.5b	UK£312.7m	21.9x	24.5x	1.2x
Sun, 31 Dec 2023	UK£7.7b	UK£6.5b	UK£312.7m	21.9x	24.5x	1.2x
Tue, 28 Nov 2023	UK£7.5b	UK£6.5b	UK£315.4m	17.3x	23.8x	1.2x
Thu, 26 Oct 2023	UK£7.5b	UK£6.5b	UK£308.8m	22.4x	24.2x	1.2x
Sat, 23 Sep 2023	UK£7.7b	UK£6.5b	UK£307.8m	22.3x	24.9x	1.2x
Mon, 21 Aug 2023	UK£8.1b	UK£6.4b	UK£286.4m	23.5x	28.2x	1.3x
Wed, 19 Jul 2023	UK£7.9b	UK£6.4b	UK£286.2m	22.7x	27.4x	1.2x
Fri, 16 Jun 2023	UK£8.0b	UK£6.4b	UK£285.1m	36.1x	28.1x	1.3x


GB Market	-0.021%
Healthcare	2.69%
Healthcare Services	-1.06%
Healthcare Facilities	0.075%
Healthcare Distributors	0%	0
Healthcare Services	-4.12%

	Company	Last Price	7D	1Y	Valuation
	MPAL MedPal AI	UK£0.031	14.8% +UK£2.5m	n/a	PS11.9x
	ICON Iconic Labs	UK£0.017	28.3% +UK£58.4k	-51.4%	PE-0.4x

Announcement • May 22

MedPal AI plc Launches New Health, Dedicated Consumer Sub-Brand

MedPal AI plc had announced the launch of New Health, a dedicated consumer sub-brand focused on the GLP-1 weight-management and broader peptide medicines market opportunity, supported by a GBP 1.3 million national consumer marketing campaign. The launch is being positioned in the context of rapid growth in the GLP-1 category and ahead of the Board's anticipated UK approval of Novo Nordisk's once-daily weight-management pill in summer 2026. New Health will sit separately from the broader MedPal Clinic app and MedPal consumer platform. It has been created to give the Company a sharper consumer brand, acquisition funnel and patient journey for the highly competitive GLP-1 category, while continuing to use MedPal AI's regulated healthcare infrastructure comprising: AI-assisted intake, clinician-led assessment, prescribing where clinically appropriate, automated pharmacy dispensing and ongoing monitoring. GBP 1.3 million has been committed to a national consumer marketing programme, with performance-led digital activity expected to be a principal component. Marketing campaign is designed to drive traffic to websites new.co.uk and new.uk, to increase initiations of qualified consultations and to grow the New Health recurring patient base. The Board anticipates that the potential UK approval of Novo Nordisk's oral Wegovy pill this summer could broaden the addressable market by attracting patients who may not previously have considered injection-based treatment. New Health will be underpinned by MedPal AI's NHS-contracted dispensing hubs in Runcorn and Swaffham, Distance Selling Pharmacy licences, direct supply agreements with Eli Lilly and Novo Nordisk for current GLP-1 medicines, and an AI layer built on Google Vertex AI. The Board notes published market research indicating that the GLP-1 category is expanding rapidly. Morgan Stanley Research has forecast that the global market for GLP-1 treatments could reach approximately GBP 140 billion by 2035, more than double reported 2025 levels. In the UK, Grand View Research estimates that the UK prescription weight-loss medications market was approximately GBP 313 million in 2025 and is projected to reach approximately GBP 1.85 billion by 2033, representing a compound annual growth rate of approximately 25% from 2026 to 2033. IQVIA evidence submitted to the UK Parliament also points to rapid private-market growth, indicating that more than 2,370,000 UK citizens had access to GLP-1s in July 2025, of which approximately 200,000 accessed treatment through the NHS. The Board anticipates that Novo Nordisk's once-daily oral semaglutide 25 mg weight-management pill, approved by the FDA in December 2025 and submitted to the EMA and other regulatory authorities during the second half of 2025, could receive UK approval during summer 2026. The Board believes that a pill-based GLP-1 option could bring a new cohort of customers into the market, including patients who may be reluctant to start injection-based treatment. The GBP 1.3 million marketing programme is intended to establish New Health as a recognised consumer entry point for eligible patients seeking regulated weight-management support. Target audiences will include UK adults actively researching weight-loss support, GLP-1 treatment options, obesity and metabolic health, as well as consumers who may become interested in tablet-based or other peptide-led treatment options as and when they are approved and clinically available in the UK. The Board expects oral GLP-1 availability, if approved, to broaden the top of the acquisition funnel and bring a new cohort of customers into the category. The marketing spend is expected to be phased over six months and performance-led, with digital channels such as Google expected to be a principal component. Management will monitor traffic to new.co.uk, initial consultations, completed clinical assessments, conversion to new patient sign-ups, retention, customer acquisition cost and gross contribution, with the ability to increase, reduce or reallocate spend according to unit economics, patient-safety requirements and clinical/pharmacy capacity. All New Health services and communications will be delivered subject to clinical eligibility, medicine availability, appropriate clinician review, prescription-only medicine rules and all applicable UK pharmacy, clinical governance and advertising requirements. CEO Jason Drummond owns the domain names new.co.uk and new.uk and has agreed to licence them to the Company for nil consideration for an initial period of six months. The provision of the domain licences constitutes a related party transaction for the purposes of AIM Rule 13. The directors of the Company, with the exception of Jason Drummond, having consulted with Cairn Financial Advisers LLP, the Company's nominated adviser, consider that the terms of the transaction are fair and reasonable insofar as the Company's shareholders are concerned. At the end of six months, the Company will have the option to acquire the domain names.

U.K. (FTSE) Healthcare Services Industry Analysis

Industry Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

IDHC: Dividend Visibility And Higher Revenue Assumptions Will Support Re Rating

CVSG: Activist Buyback Push And Index Inclusion Will Support Future Upside

GENinCode Plc to Report Fiscal Year 2025 Results on May 22, 2026

MedPal AI plc Launches New Health, Dedicated Consumer Sub-Brand

Less than half of directors are independent

New major risk - Shareholder dilution